drugset / Trial / NCT04421352

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

NCT04421352

Phase 1 Completed 11 enrolled CStone Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients

Timeline

Start
2021-01-12
Primary completion
2023-12-22
Completion
2023-12-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sugemalimab Monoclonal antibody 1200 mg